Bioluminescence imaging-based screening assay and inhibitors of abcg2
AssigneeThe Johns Hopkins University
InventorsMARTIN GILBERT POMPER, YIMAO ZHANG, JOHN LATERRA
Life of this patent
Estimating the term…
Abstract
A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described.
Claims23
A method for identifying inhibitors of ABCG2 comprising imaging at least one culture comprising a test compound, luciferin and cells that express ABCG2 and firefly luciferase;
- and selecting a test compound resulting in at least two-fold bioluminescence signal enchancement as an ABCG2 inhibitor.
(canceled)
A method of treating a cellular proliferative disorder comprising administering to a patient in need of treatment a therapeutic amount of a compound selected from the group consisting of the compounds of Tables 2-6, optionally together with a therapeutically effective amount of a chemotherapeutic agent different from the ABCG2 inhibitor.
17-21. (canceled)
A method of imaging cells, tumors, tissues or organs that express ABCG2 comprising administering an effective amount of an ABCG2 inhibitor selected from the group consisting of the compounds listed in Tables 2-6, labeled with one or more radioisotopes.
(canceled)
Dependencies are inferred from the claim text.